Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.37 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.37 |
| ▸ | CDC42BPA | Q5VT25 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3464379 | 0.91 | ROCK2 (0.34) | ROCK2ROCK1CDC42BPBHDAC4 | |
| SCHEMBL3463968 | 0.85 | HDAC4 (0.34) | HDAC4 | |
| SCHEMBL3463550 | 0.85 | CYP11B2 (0.48) | CYP2D6CYP3A4CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL3465225 | 0.84 | CHRNB2 (0.39) | ALDH1A1CYP2D6CYP3A4CYP1A2USP2 | |
| SCHEMBL3463377 | 0.82 | DRD2 (0.36) | ALDH1A1CYP2D6CYP3A4CYP1A2USP2 | |
| SCHEMBL3464138 | 0.82 | CHRNB2 (0.43) | ALDH1A1 | |
| SCHEMBL3463652 | 0.79 | CHRNB2 (0.43) | ROCK2ROCK1AKT1 | |
| SCHEMBL3463093 | 0.78 | CHRNB2 (0.39) | ALDH1A1 | |
| SCHEMBL3464644 | 0.78 | ESR2 (0.35) | ALDH1A1CYP2D6CYP3A4CYP1A2USP2 | |
| SCHEMBL3463841 | 0.78 | CHRNB2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | claimed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | claimed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | claimed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754708-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | BHATTI BALWINDER | 2008-10-02 | — | — | US | disclosed |
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | disclosed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | MUSK, TNNC1, CHRNA5 | ROCK2 2888/4885ROCK1 3111/4885CDC42BPB 1177/4885 |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | MUSK, TNNC1, CHRNA5 | ROCK2 2888/4885ROCK1 3111/4885CDC42BPB 1177/4885 |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | OPRL1, OPRK1, ACHE | ROCK2 3501/4885ROCK1 3532/4885CDC42BPB 2167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.